

Anti-IL-5Ra/ CD125 Antibody (Benralizumab)

Introduction

Benralizumab (MEDI-563) is an interleukin 5 receptor alpha (IL-5R α)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils by enhancing antibody-dependent cell-mediated cytotoxicity. All. Benralizumab is indicated for severe eosinophilic asthma.

Product parameters

Alternative Names	Fasenra, MEDI-563, BIW-8405
Target Accession	Q01344
Target	IL-5Ra/ CD125
CAS number	1044511-01-4
Molecular Weight	146.06 kDa
Host	CHO
Reactivity	Human, Mouse, Rat
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL 5R α His at 2 ug/mL can bind Anti-IL-5Ra/ CD125 Antibody (Benralizumab), EC50=0.001639 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

